Topical pharmaceutical composition comprising amitriptyline and basic aqueous phase

The permeability and tolerance of amitriptyline in the treatment of peripheral neuropathic pain and erythematosus limb pain is solved by adopting an oil-in-water emulsion form and a high pH aqueous phase in amitriptyline pharmaceutical composition. Effective pain relief and good local application performance are achieved.

CN119033741APending Publication Date: 2024-11-29ALGOTHERAPEUTIX
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411156354.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-03-19
Filing Date
2022-03-15
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing amitriptyline pharmaceutical compositions have adverse effects caused by high concentrations in the treatment of peripheral neuropathic pain and are difficult to effectively penetrate the skin, especially in neuropathic pain caused by chemotherapy and erythematosus limb pain. limited.

Method used

A pharmaceutical composition in the form of an oil-in-water emulsion is developed, containing 1% to 30% of the alkaline amitriptyline oil phase and an aqueous phase with a pH of more than or equal to 7, using ingredients such as surfactants and polyols, Emulsion forms are formed to improve permeability and bioavailability of amitriptyline.

Benefits of technology

This composition can effectively pass through the skin, reduce the risk of adverse effects of amitriptyline, significantly improve the pain treatment effect, and show good tolerance and odorless and comfortable touch characteristics in local applications. It is suitable for chemotherapy-induced Treatment of peripheral neuropathic pain, postherpetic neuropathic pain and diabetic neuropathic pain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005005086850000031
    Figure BDA0005005086850000031
Patent Text Reader

Abstract

The present invention relates to a topical pharmaceutical composition in the form of an oil-in-water emulsion comprising an oil phase based on amitriptyline in a basic form and a basic aqueous phase. The invention also relates to a pharmaceutical composition according to the invention for topical use in the treatment of neuropathic pain and erythromelalgia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application filed on March 15, 2022, with the invention name “Topical pharmaceutical composition comprising amitriptyline and an alkaline aqueous phase” and application number 202280022714.5.

[0002] The present invention relates to a topical pharmaceutical composition in the form of an oil-in-water emulsion comprising an oily phase based on amitriptyline in basic form and a basic aqueous phase.

[0003] The invention also relates to the use of the pharmaceutical composition according to the invention for the preparation of a medicinal product for the local treatment of neuropathic pain and erythromelalgia.

[0004] Peripheral neuropathic pain is caused by damage to neural structures (such as peripheral nerve endings or nociceptors) that become extremely sensitive to stimulation and may produce impulses in the absence of stimulation.

[0005] This damage may result from a variety of causes, such as trauma, disease (e.g., diabetes, herpes zoster, and advanced cancer), chemotherapy treatment, or chemical burns. Peripheral nerve damage may result in a pathological condition characterized by the presence of persistent spontaneous pain, superficial (burning or cold pain) or deep (pressure or vice), paroxysmal pain (electric shock, stabbing) with hypoesthesia or, on clinical examination, hyperalgesia (increased response to noxious stimuli), allodynia (pain caused by non-painful stimuli), or hyperalgesia (persistent pain during ordinary repetitive non-noxious stimuli). Neuropathy may also be associated with sensory signs (e.g., paresthesias, numbness, and pruritus).

[0006] Chemotherapy-induced neuropathies are particularly common, disabling, and difficult to treat. They are dose-dependent. Peripheral nerve damage represents the majority of neurological damage associated with chemotherapy toxicity. They are the result of direct toxic damage to axons or demyelination and represent the most common limiting factor following hematologic toxicity.

[0007] Algotherapeutix's previously filed application WO 2018 / 197307 and the article "Rossignol, J. et al. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies. Support Care Cancer 27, 3053-3059 (2019)" describe the topical use of a pharmaceutical composition in the form of a cream with a high amitriptyline concentration and a slightly acidic pH in the treatment of peripheral neuropathic pain.

[0008] Application FR 2 003 425 (registration number) previously filed by Algotherapeutix describes the topical use of a pharmaceutical composition in the form of a gel with a high amitriptyline concentration and an acidic pH in the treatment of peripheral neuropathic pain.

[0009] There is a real need to develop and provide new compositions based on amitriptyline which have good effectiveness, and possibly improved effectiveness, in dermal application for the treatment of pain, in particular in the treatment of peripheral neuropathic pain and in particular chemotherapy-induced neuropathic pain.

[0010] Furthermore, amitriptyline, like all tricyclic antidepressants, may have numerous adverse effects (arterial hypotension, sedation, QT interval prolongation), especially when administered orally.

[0011] Therefore, it is also of interest to formulate new compositions with low amitriptyline concentrations to reduce the risk of adverse effects while maintaining good, and possibly improving, effectiveness in dermal applications for the treatment of pain.

[0012] Surprisingly, it has been found that a pharmaceutical composition in the form of an oil-in-water emulsion for topical application, comprising an oily phase containing 1% to 30% by weight of amitriptyline in basic form, relative to the total weight of the composition, and an aqueous phase having a pH greater than or equal to 7, can effectively treat pain, in particular chemotherapy-induced peripheral neuropathic pain (or CIPN, standing for "chemotherapy-induced peripheral neuropathy"), postherpetic neuropathic pain (or PHN, standing for "postherpetic neuralgia") or diabetic neuropathic pain (or DPN, standing for "diabetic peripheral neuropathy").

[0013] In particular, this finding is even more surprising since, contrary to expectations, increasing the pH of an amitriptyline-based composition at alkaline pH does not have the effect of precipitating amitriptyline. The composition is then in the form of an emulsion comprising droplets of amitriptyline in alkaline form dispersed in an alkaline aqueous phase.

[0014] One object of the present invention is therefore a pharmaceutical composition in the form of an oil-in-water emulsion for topical application, comprising:

[0015] (i) an oily phase containing at least amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 30% by weight relative to the total weight of the composition; and

[0016] (ii) an aqueous phase having a pH greater than or equal to 7.

[0017] It has been noted that the pharmaceutical composition according to the invention is able to promote the penetration of amitriptyline through the skin, thereby achieving good therapeutic effectiveness even at low amitriptyline concentrations.

[0018] In particular, it has been observed that the compositions according to the invention having an aqueous phase with a pH higher than or equal to 7, and more preferably at a pH higher than or equal to 8, and even more preferably at a pH between 8.5 and 12 are characterized by a better penetration of amitriptyline through the skin than similar compositions having an aqueous phase with an acidic pH.

[0019] Furthermore, the composition according to the invention has good bioavailability at an amitriptyline concentration preferably between 1% and 10% by weight, more preferably between 1% and 9% by weight, relative to the total weight of the composition.

[0020] Furthermore, the composition according to the invention comprises few excipients, which promotes good local tolerability of the composition (less risk of allergies, less risk of irritation).

[0021] The composition according to the invention also has good use properties, ie the composition is odorless and has a pleasant touch.

[0022] In a particularly surprising manner, it has also been found that the pharmaceutical composition according to the invention is effective for the topical treatment of erythromelalgia.

[0023] Erythromelalgia is a rare episodic acrosyndrome that affects the lower extremities symmetrically with erythema, fever, and burning pain. Many scientific articles describe this orphan disease, notably "Leroux MB. Erythromelalgia: a cutaneous manifestation of neuropathy? An Bras Dermatol. 2018;93(1):86-94".

[0024] The topical (dermal) application of the composition according to the invention results in an effective treatment of erythromelalgia and neuropathic pain, more particularly peripheral neuropathic pain such as chemotherapy-induced, post-herpetic and diabetic peripheral neuropathic pain.

[0025] It was noted that, in addition to relieving pain, the amitriptyline-based composition was able to restore healthier skin.

[0026] Furthermore, topical application of the composition according to the invention has few or even no side effects. In particular, no skin irritation was observed where the composition was applied.

[0027] Another object of the present invention is the use of the pharmaceutical composition according to the invention for the preparation of a medicinal product, and more particularly for the local treatment of neuropathic pain, such as peripheral neuropathic pain, and for the local treatment of erythromelalgia.

[0028] Other objects, features, aspects and advantages of the present invention will become more clearly apparent after reading the description and the following examples.

[0029] In this manual, unless otherwise stated:

[0030] - the expression "at least one" is equivalent to the expression "one or more" and is therefore interchangeable;

[0031] - the expression “comprising between ... and ...” is equivalent to the expression “ranging from ... to ..." and is therefore interchangeable and means that the endpoints are included;

[0032] - In the context of the present invention, the expression "polyoxyalkylenated" corresponds to -(O-alkyl) n - units, wherein n is an integer ranging from 2 to 200, preferably from 2 to 40, more preferably from 2 to 20;

[0033] - In the context of the present invention, the expression "polyoxyethylenated" corresponds to -(O-CH2CH2)n-, wherein n is an integer varying from 2 to 200, preferably from 2 to 40, more preferably from 2 to 20.

[0034] According to the invention, the composition is in the form of an oil-in-water emulsion.The composition according to the invention is not in the form of a gel.

[0035] Preferably, the average volume size of the oil droplets of the oil-in-water emulsion according to the present invention ranges from 1 nm to 50 μm.

[0036] More preferably, the average volume size of the oil droplets in the composition according to the invention ranges from 10 nm to 20 μm, even more preferably from 100 nm to 10 μm.

[0037] In particular, the known dynamic light scattering (DLS) method can be used to determine the mean volume size of the oil droplets. As devices that can be used for this determination, there can be mentioned a Zeiss brand, Axio model microscope or a Malvem brand, Mastersizer 3000 model or Zetasizer Nano ZS model particle sizer equipped with a standard laser with a power of 4 mW and a wavelength of 633 nm. The device is also equipped with a correlator (25 ns to 8,000 s, maximum 4,000 channels).

[0038] Amitriptyline

[0039] The composition according to the invention comprises an oily phase based on amitriptyline in its basic form.

[0040] According to the present invention, the total amitriptyline content ranges from 1 wt % to 30 wt % relative to the total weight of the composition.

[0041] Amitriptyline has the following formula (I):

[0042]

[0043] Advantageously, the amitriptyline present in the composition according to the invention is in its alkaline form. In other words, the amitriptyline present in the composition according to the invention is not salified. Furthermore, the nitrogen atom of the amitriptyline present in the composition according to the invention is not protonated.

[0044] Preferably, amitriptyline in basic form constitutes the oily phase of the composition according to the invention.

[0045] According to a particular embodiment of the invention, the composition according to the invention may further comprise one or more liquid fatty substances other than amitriptyline.

[0046] Preferably, the total content of amitriptyline ranges from 1 wt% to 10 wt%, more preferably from 1 wt% to 9 wt%, even more preferably from 1 wt% to 8 wt%, and more preferably from 1 wt% to 7 wt%, relative to the total weight of the composition.

[0047] In particular, better penetration of amitriptyline through the skin is observed when the total content of amitriptyline ranges from 1% to 10% by weight, better from 1% to 9% by weight, better from 1% to 8% by weight and even better from 1% to 7% by weight relative to the total weight of the composition according to the invention.

[0048] water

[0049] The composition according to the invention comprises water.

[0050] Preferably, the total moisture content is greater than or equal to 75% by weight, more preferably comprised between 75% and 95% by weight; even more preferably between 75% and 90% by weight relative to the total weight of the composition.

[0051] Surfactants

[0052] Preferably, the composition according to the invention further comprises at least one surfactant.

[0053] The surfactants that can be used according to the present invention may be selected from anionic surfactants, cationic surfactants, amphoteric or zwitterionic surfactants, nonionic surfactants and mixtures thereof.

[0054] More preferably, the one or more surfactants that may be used according to the present invention are selected from nonionic surfactants.

[0055] The nonionic surfactants that can be used according to the invention can be chosen from alkyl polyglucosides (APGs), oxyalkylenated glycerides, oxyalkylenated fatty acid and sorbitan esters, polyoxyalkylenated fatty acid esters (in particular polyoxyethylenated and / or polyoxypropylenated), optionally in combination with fatty acids and glycerides such as a PEG-100 stearate / glyceryl stearate mixture (for example marketed under the name Arlacel 165 by the company ICI), oxyalkylenated sugar esters and mixtures thereof.

[0056] As alkyl polyglucosides, mention may be made of those containing an alkyl group comprising 6 to 30 carbon atoms, and preferably 8 to 16 carbon atoms, and containing a glucoside group preferably comprising 1.2 to 3 glucoside units. For example, the alkyl polyglucosides may be chosen from decyl glucoside (alkyl-C9 / C 11 - polyglucosides (1.4)), such as those marketed by Kao Chemicals under the name Mydol The product is marketed by Cognis under the name Plantacare 2000 Commercially available products; Capryl / decanoyl glucoside, such as that sold by Cognis under the name Plantacare KE Commercially available products; Lauryl glucoside, such as that marketed by the company Cognis under the name Plantacare 1200 Commercially available products; Coco-glucoside, such as Plantacare 818 from Cognis Commercially available products; Caprylyl glucoside, such as that sold by Cognis under the name Plantacare 810 Commercially available products; and mixtures thereof.

[0057] Polyoxyalkylened glycerides are in particular polyoxyethylened derivatives of glyceryl esters and fatty acid esters and their hydrogenated derivatives. These oxyethylened glycerides may be chosen, for example, from esters of glyceryl with hydrogenated and oxyethylened fatty acids, such as PEG-200 hydrogenated palmitic glyceride (sold under the name Rewoderm LI-S 80 by the company Goldschmidt); oxyethylened glyceryl cocoates, such as PEG-7 glyceryl cocoate (sold under the name Tegosoft GC by the company Goldschmidt) and PEG-30 glyceryl cocoate (sold under the name Rewoderm LI-63 by the company Goldschmidt); oxyethylened stearic glyceryl; and mixtures thereof.

[0058] In particular, oxyalkylenated sugar esters are polyethylene glycol ethers of fatty acids and sugar esters. For example, these oxyalkylenated sugar esters may be chosen from oxyethylenated glucose esters, such as PEG-120 methyl glucose dioleate (commercially available under the name Glucamate DOE 120 by the company Amerchol).

[0059] Preferably, the number of moles of alkylene oxide of the nonionic surfactants that can be used according to the invention varies from 2 to 400; more preferably from 4 to 250.

[0060] Preferably, the composition according to the invention comprises at least one nonionic surfactant; more preferably a nonionic surfactant (optionally polyoxyalkylenated) chosen from sorbitan esters, glycerides and mixtures thereof; even more preferably chosen from polyoxyalkylenated glycerides; even more preferably chosen from hydrogenated and polyoxyethylenated glycerides and fatty acids, polyoxyethylenated cocoglyceryl, polyoxyethylenated stearyl glyceryl and mixtures thereof.

[0061] Preferably, when the composition according to the invention comprises at least one surfactant, the total content of surfactant(s) is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 4% by weight relative to the total weight of the composition.

[0062] Preferably, when the composition according to the invention comprises at least one surfactant, the total content of nonionic surfactant(s) is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 4% by weight relative to the total weight of the composition.

[0063] Polyols

[0064] Preferably, the composition according to the invention further comprises at least one C2-C8 polyol.

[0065] In the context of the present invention, "C2-C8 polyol" is understood to be an organic compound consisting of a C2-C8 hydrocarbon chain optionally interrupted by one or more oxygen atoms and carrying at least two free hydroxyl groups (-OH) carried by different carbon atoms, which compound may be cyclic or acyclic, linear or branched, saturated or unsaturated, and has a low molecular weight at room temperature (25°C) and atmospheric pressure (i.e. 1.013x10 5 Pa) is in liquid state.

[0066] Preferably, the one or more C2-C8 polyols according to the present invention are acyclic and non-aromatic.

[0067] The C2-C8 polyol according to the present invention contains 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, more preferably 2 to 5 carbon atoms in its structure.

[0068] More specifically, the polyol or polyols that can be used according to the invention contain 2 to 10 hydroxyl groups, more preferably 2 to 5 hydroxyl groups, more preferably 2 to 3 hydroxyl groups.

[0069] Preferably, the one or more C2-C8 polyols that may be used according to the present invention are selected from C3-C6 polyols, ethylene glycol and mixtures thereof.

[0070] According to a preferred embodiment of the present invention, the one or more C2-C8 polyols that can be used according to the present invention are selected from propylene glycol, 1,3-propanediol, 1,3-butanediol, pentane-1,2-diol, dipropylene glycol, hexylene glycol, pentylene glycol, glycerol, ethylene glycol and mixtures of these compounds; more preferably, the composition contains at least propylene glycol.

[0071] Preferably, when the composition according to the invention comprises at least one C2-C8 polyol, the total content of the C2-C8 polyol(s) is comprised between 0.1 and 15% by weight, more preferably between 0.5 and 10% by weight, even more preferably between 1 and 6% by weight and better still between 3 and 6% by weight relative to the total weight of the composition.

[0072] Preferably, when the composition according to the invention comprises at least one C2-C8 polyol, the total propylene glycol content is comprised between 0.1 and 15% by weight, more preferably between 0.5 and 10% by weight, even more preferably between 1 and 6% by weight and better still between 3 and 6% by weight relative to the total weight of the composition.

[0073] Thickener

[0074] Preferably, the composition according to the invention further comprises at least one thickener.

[0075] More preferably, the one or more thickeners are thickening polymers.

[0076] According to the invention, a "thickening polymer" is understood to mean a polymer which has a high viscosity at room temperature (25° C.), at atmospheric pressure and at 1 s -1 A polymer having a shear rate of at least 20 cps (20 mPa.s), preferably at least 50 cps (50 mPa.s), by whose presence at a concentration of 0.05 wt.% the viscosity of the cosmetic compositions into which they are introduced increases (viscosity can be measured using a cone / plane viscometer, a Haake R600 rheometer or equivalent equipment).

[0077] As examples of thickeners, mention may be made of crosslinked homopolymers or copolymers of acrylic acid or methacrylic acid, crosslinked homopolymers of 2-acrylamido-2-methyl-propanesulfonic acid and crosslinked acrylamide copolymers thereof, homopolymers of ammonium acrylate or copolymers of ammonium acrylate and acrylamide, cellulosic polymers, and mixtures thereof.

[0078] Among the crosslinked homopolymers of acrylic acid, mention may be made of those crosslinked with allyl alcohol ethers of the sugar series, such as the products sold under the names CARBOPOLS 980, 981, 954, 2984 and 5984 by the company NOVEON or the products sold under the names SYNTHALEN M and SYNTHALEN K by the company 3VSA. These polymers have the INCI name Carbomer. The thickening polymer may also be a crosslinked copolymer of (meth)acrylic acid, such as the polymer sold under the name AQUA SF1 by the company NOVEON.

[0079] Even more preferably, the composition according to the invention further comprises at least one cellulosic polymer.

[0080] According to the invention, a "cellulose" polymer is understood to be any polysaccharide compound (whether substituted or not) having glucose residues linked by β-1,4 bonds in its structural chain. In addition to unsubstituted cellulose, cellulose derivatives may be anionic, cationic, amphoteric or nonionic.

[0081] Thus, the cellulose polymers that may be used according to the present invention may be selected from unsubstituted cellulose (including microcrystalline forms) and substituted cellulose.

[0082] More preferably, the cellulosic polymers that can be used according to the invention do not contain C 10 -C 30 Fatty side chains.

[0083] Preferably, the cellulosic polymer or polymers that can be used according to the invention have an average molecular weight comprised between 5,000 and 1,500,000, more preferably between 50,000 and 800,000, even more preferably between 400,000 and 800,000.

[0084] Among the cellulose polymers according to the invention, a distinction can be made between cellulose ethers, cellulose esters and cellulose ether esters.

[0085] Among the cellulose esters, mention may be made of inorganic cellulose esters (cellulose nitrates, sulfates or phosphates ...), organic cellulose esters (cellulose monoacetates, triacetates, amidopropionates, acetate butyrates, acetate propionates or acetate trimellitates ...) and mixed organic / inorganic cellulose esters (e.g. cellulose acetate butyrate sulfate and cellulose acetate propionate sulfate). Among the cellulose ether esters, mention may be made of hydroxypropyl methylcellulose phthalate and ethyl cellulose sulfate.

[0086] Among the nonionic cellulose ethers, mention may be made of (C1-C4)alkylcelluloses, such as methylcellulose and ethylcellulose (e.g. Ethocel standard 100 Premium from DOW CHEMICAL); (poly)hydroxy(C1-C4)alkylcelluloses, such as hydroxymethylcellulose, hydroxyethylcellulose (e.g. Natrosol 250HHR supplied by AQUALON) and hydroxypropylcellulose (e.g. Klucel EF supplied by AQUALON); mixed (poly)hydroxy(C1-C4)alkyl-(C1-C4)alkylcelluloses such as hydroxypropyl-methylcellulose (e.g. Methocel E4M from DOW CHEMICAL), hydroxyethyl-methylcellulose, hydroxyethyl-ethylcellulose (e.g. Bermocoll E 481 FQ from AKZO NOBEL) and hydroxybutylmethylcellulose.

[0087] Among the anionic cellulose ethers, mention may be made of (poly)carboxy(C1-C4)alkylcellulose and its salts. Mention may be made, by way of example, of carboxymethylcellulose, carboxymethylmethylcellulose (for example Blanose 7M from the company AQUALON) and carboxymethylhydroxyethylcellulose and its sodium salt.

[0088] Among the cationic cellulose ethers, mention may be made of cationic cellulose derivatives, such as cellulose copolymers or cellulose derivatives grafted with water-soluble quaternary ammonium monomers and described in particular in patent US 4 131 576, for example (poly)hydroxy(C1-C4)alkylcelluloses, such as hydroxymethyl-, hydroxyethyl- or hydroxypropylcellulose grafted in particular with methacryloylethyl-trimethylammonium, methacrylamidopropyl-trimethylammonium or dimethyl-diallylammonium salts. More particularly, commercial products meeting this definition are those sold by the company National Starch under the name “ L 200" and " H 100” products for sale.

[0089] According to a preferred embodiment of the present invention, the one or more cellulose polymers are selected from the group consisting of 10 -C30 Cellulosic polymers with fatty side chains are more preferably selected from cellulose ethers; even more preferably selected from nonionic cellulose ethers; more preferably selected from (a) (C1-C4) alkyl celluloses, such as methyl cellulose and ethyl cellulose, (b) (poly) hydroxy (C1-C4) alkyl celluloses, such as hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose, (c) mixed (poly) hydroxy (C1-C4) alkyl-(C1-C4) alkyl celluloses, such as hydroxypropyl-methyl cellulose, hydroxypropyl-ethyl cellulose, hydroxyethyl-methyl cellulose, hydroxyethyl-ethyl cellulose and hydroxybutyl-methyl cellulose, and (d) mixtures thereof.

[0090] More preferably, the composition according to the invention comprises at least one (poly)hydroxy(C1-C4)alkylcellulose, such as hydroxymethylcellulose, hydroxyethylcellulose and hydroxypropylcellulose; more preferably at least hydroxyethylcellulose.

[0091] Preferably, when the composition according to the invention comprises at least one thickener, the total content of thickener(s) is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 2.5% by weight relative to the total weight of the composition.

[0092] Preferably, when the composition according to the invention comprises at least one cellulosic polymer, the total content of the cellulosic polymer(s) is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 2.5% by weight, relative to the total weight of the composition.

[0093] Preferably, when the composition according to the invention comprises at least one cellulosic polymer, the total content of one or more (poly)hydroxy (C1-C4) alkyl celluloses is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 2.5% by weight, relative to the total weight of the composition.

[0094] Preferably, when the composition according to the invention comprises at least one cellulosic polymer, the total content of hydroxyethylcellulose is comprised between 0.1% and 10% by weight, more preferably between 0.5% and 5% by weight, even more preferably between 1% and 2.5% by weight relative to the total weight of the composition.

[0095] Liquid fatty substances

[0096] The composition according to the invention may further comprise at least one liquid fatty substance.

[0097] In the context of the present invention, "fatty substances" are understood to be fatty substances at 30°C and at atmospheric pressure (760 mm Hg or 1.013 x 10 5 Pa) Organic compounds which are insoluble in water, ie have a solubility lower than 5%, and preferably lower than 1%, even more preferably lower than 0.1% (g / mL water).

[0098] Generally speaking, liquid fatty substances are soluble in organic solvents such as chloroform, ethanol or benzene under the same temperature and pressure conditions.

[0099] In the context of the present invention, "liquid fatty substance" is understood to be a fatty substance in a liquid state at 25°C and atmospheric pressure (760 mm Hg or 1.013 x 10 5 Pa) Fatty substances in liquid state.

[0100] Preferably, they are at a temperature of 25°C and at 1 s -1 The shear rate has a viscosity lower than or equal to 2 Pa.s, better still lower than or equal to 1 Pa.s and even better still lower than or equal to 0.1 Pa.s.

[0101] The liquid fatty substances that can be used in the composition according to the invention are generally not oxyalkylenated and preferably do not contain any COOH carboxylic acid functions.

[0102] Advantageously, the liquid fatty substance according to the invention may be chosen from hydrocarbons, fatty alcohols preferably comprising from 8 to 40 carbon atoms, fatty esters preferably comprising from 8 to 40 carbon atoms, fatty ethers preferably comprising from 8 to 40 carbon atoms, silicones and mixtures thereof.

[0103] Liquid hydrocarbons are understood to be composed only of carbon and hydrogen atoms (at a temperature of 25° C. and at atmospheric pressure (760 mm Hg, i.e. 1.013 x 10 5 Pa) is a liquid), a hydrocarbon of mineral or vegetable or synthetic origin.

[0104] More specifically, the liquid hydrocarbon is selected from:

[0105] - straight-chain or branched, optionally cyclic C6-C 16 Alkanes. For example, there may be mentioned hexane, undecane, dodecane, tridecane and isoparaffins (such as isohexadecane, isododecane and isodecane), and mixtures thereof.

[0106] - linear or branched hydrocarbons of mineral, animal or synthetic origin, having more than 16 carbon atoms, such as paraffin or vaseline, petrolatum, polydecene, hydrogenated polyisobutene (for example, those sold by brands), squalane.

[0107] Liquid fatty alcohols are understood to be non-glycerolated and non-oxyalkylened fatty alcohols which are 5 Pa) is a liquid.

[0108] Preferably, the liquid fatty alcohol of the present invention contains 8 to 30 carbon atoms, more preferably 8 to 20 carbon atoms.

[0109] The liquid fatty alcohols of the present invention may be saturated or unsaturated.

[0110] Preferably, the saturated liquid fatty alcohols are branched. They may or may not contain at least one aromatic ring in their structure. Preferably, they are acyclic.

[0111] More specifically, the liquid saturated fatty alcohol of the present invention is chosen from octyldodecanol, isostearyl alcohol and 2-hexyldecanol.

[0112] The liquid unsaturated fatty alcohol has at least one double bond or triple bond in its structure, and preferably has one or more double bonds. When there are multiple double bonds, their number is preferably 2 or 3, and they may be conjugated or not.

[0113] These unsaturated fatty alcohols may be straight chain or branched chain.

[0114] They may or may not contain at least one aromatic ring in their structure. Preferably, they are acyclic.

[0115] More specifically, the liquid unsaturated fatty alcohol of the present invention is selected from oleic (or oleyl) alcohol, linoleic (or linoleyl) alcohol, linolenic (or linolenyl) alcohol and undecenyl alcohol.

[0116] Liquid fatty esters are understood to be esters derived from fatty acids and / or fatty alcohols which are stable at 30° C. and at atmospheric pressure (760 mm Hg, i.e. 1.013×10 5 Pa) are liquid and are different from fatty acids and (poly)glycerol monoesters.

[0117] Preferably, the liquid fatty ester is a saturated or unsaturated, linear or branched C1-C 26 Liquid esters of aliphatic monobasic or polybasic acids and saturated or unsaturated, linear or branched C1-C 26 Liquid esters of aliphatic monohydric or polyhydric alcohols, the total number of carbon atoms of the liquid ester is greater than or equal to 10.

[0118] Preferably, for fatty esters of monohydric alcohols, at least one of the alcohol or acid derived from the esters of the present invention is branched.

[0119] Among the monoesters of monoacids and monoalcohols, mention may be made of ethyl and isopropyl palmitate, alkyl myristates (for example isopropyl or ethyl myristate), isocetyl stearate, ethyl laurate, 2-ethylhexyl isononanoate, isononyl isononanoate, ethyl caprylate, ethyl caprylate, isodecyl neopentanoate, and isostearyl neopentanoate.

[0120] Dicarboxylic or tricarboxylic acids with C1-C 22 Alcohol C4-C 22 Esters and monocarboxylic acids, dicarboxylic acids or tricarboxylic acids with C4-C 26 Esters of di-, tri-, tetra- or pentahydroxylated non-sugar alcohols may also be used.

[0121] Finally, it is also possible to use natural or synthetic esters of di- or tri-acids with glycerol.

[0122] Among them, mention may be made of vegetable oils or oils of vegetable origin.

[0123] As oils of vegetable origin or synthetic triglycerides that can be used as liquid fatty esters in the composition according to the invention, mention may be made, for example, of triglyceride oils of vegetable or synthetic origin, for example liquid triglycerides of fatty acids containing from 6 to 30 carbon atoms, such as triglycerides of heptanoic acid or caprylic acid, or for example sunflower, corn, soy, pumpkin, grapeseed, sesame, hazelnut, apricot, macadamia, arara, sunflower, castor, avocado, olive, rapeseed, copra, wheat germ, sweet almond, apricot, safflower, castanea, camelina, tamanu, babassu and bacas oils, caprylic / capric triglycerides such as those sold by the company STEARINERIES DU BOIS or those sold under the name VIZIONE by the company DYNAMIT NOBEL those sold by 810, 812 and 818), jojoba oil, shea butter.

[0124] The oil or oils that may be used in the composition according to the invention may also be chosen from silicones.

[0125] Preferably, the one or more liquid silicones are chosen from polydialkylsiloxanes, in particular polydimethylsiloxanes (PDMS), and organomodified polysiloxanes comprising at least one functional group chosen from amino groups, aryl groups and alkoxy groups.

[0126] Organopolysiloxanes are defined in more detail in the book "Chemistry and Technology of Silicones" by Walter NOLL (1968), Academy Press.

[0127] The organomodified silicones that can be used according to the invention are silicones as defined previously and which contain in their structure one or more organofunctional groups fixed by hydrocarbon groups.

[0128] The organomodified silicones may be polydiarylsiloxanes, in particular polydiphenylsiloxanes, and also polyalkyl-arylsiloxanes functionalized with the abovementioned organofunctional groups.

[0129] The liquid fatty substance or substances according to the invention are different from amitriptyline and the surfactants described previously.

[0130] According to a particular embodiment of the invention, the composition further comprises at least one liquid fatty substance chosen from hydrocarbons, fatty esters comprising from 8 to 40 carbon atoms, silicones and mixtures thereof.

[0131] Preferably, the total content of liquid fatty substance(s) is comprised between 0% and 20% by weight, more preferably between 0% and 10% by weight relative to the total weight of the composition.

[0132] More preferably, the composition according to the invention does not comprise any liquid fatty substance (other than amitriptyline and the aforementioned surfactants).

[0133] The composition according to the present invention may further contain additives commonly used in medicines, such as one or more flavors and / or antibacterial agents.

[0134] As the antibacterial agent, parabens (eg, methylparaben or propylparaben), phenoxyethanol, and isothiazolinone, and more preferably isothiazolinone (eg, benzisothiazolinone, methylisothiazolinone, and / or methylchloroisothiazolinone) are preferably used.

[0135] These additives may be present in the composition according to the invention in an amount ranging from 0% to 20% by weight relative to the total weight of the composition.

[0136] A person skilled in the art will ensure that these possible additives and their amounts are chosen such that they do not affect the properties of the composition of the invention.

[0137] The pH of the aqueous phase of the composition according to the invention is greater than or equal to 7.

[0138] Preferably, the pH of the aqueous phase is greater than or equal to 8, more preferably the pH ranges from 8 to 13, even more preferably from 8.5 to 13, more preferably from 9 to 12.5, even more preferably from 9 to 12.

[0139] According to one variant of the invention, the pH of the composition according to the invention is comprised between 7 and 8.

[0140] The pH can be adjusted to the desired value using customary alkalizing agents. Among the alkalizing agents, mention may be made, for example, of ammonia, alkanolamines, inorganic or organic hydroxides. The composition according to the invention may contain one or more alkalizing agents as mentioned above.

[0141] To adjust the pH, the composition according to the invention may comprise one or more buffer solutions.

[0142] As examples, mention may be made of phosphate, citrate, borate, sorbate, acetate or tris-EDTA buffers. These buffers are commercially available, in particular, from the companies Fischer or VWR.

[0143] According to a preferred embodiment of the present invention, the composition comprises:

[0144] (i) an oily phase containing at least amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 10% by weight, preferably from 1% to 9% by weight, more preferably from 1% to 8% by weight, even more preferably from 1% to 7% by weight, relative to the total weight of the composition; and

[0145] (ii) an aqueous phase having a pH greater than or equal to 7.

[0146] According to a specific embodiment of the present invention, the composition comprises:

[0147] (i) an oily phase consisting of amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 10% by weight, preferably from 1% to 9% by weight, more preferably from 1% to 8% by weight, even more preferably from 1% to 7% by weight, relative to the total weight of the composition;

[0148] (ii) an aqueous phase having a pH greater than or equal to 7.

[0149] According to a variant of the invention, the composition comprises:

[0150] (i) an oily phase containing at least amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 10% by weight, preferably from 1% to 9% by weight, more preferably from 1% to 8% by weight, even more preferably from 1% to 7% by weight, relative to the total weight of the composition; and

[0151] (ii) an aqueous phase having a pH comprised between 7 and 8.

[0152] The present invention is a composition as described hereinbefore for topical use thereof. The composition according to the present invention is a composition suitable for topical application.

[0153] Another object of the present invention is also the use of the pharmaceutical composition according to the present invention as described above for the preparation of a medicinal product.

[0154] Another object of the present invention is also the composition according to the invention as described above for its use as a medicinal product.

[0155] Another object of the present invention is the use of the pharmaceutical composition according to the present invention as described above for the preparation of a medicinal product for the local treatment of neuropathic pain; preferably for the local treatment of peripheral neuropathic pain; more preferably for the local treatment of chemotherapy-induced peripheral neuropathic pain, post-herpetic neuropathic pain, diabetic neuropathic pain; even more preferably for the local treatment of chemotherapy-induced peripheral neuropathic pain.

[0156] Another object of the present invention is the composition according to the present invention as described above for its topical use in the treatment of neuropathic pain; preferably for its topical use in the treatment of peripheral neuropathic pain; more preferably for its topical use in the treatment of chemotherapy-induced peripheral neuropathic pain, post-herpetic neuropathic pain, diabetic neuropathic pain; even more preferably for its topical use in the treatment of chemotherapy-induced peripheral neuropathic pain.

[0157] Another object of the present invention is the use of a pharmaceutical composition according to the invention as described above for the preparation of a medicinal product for the topical treatment of erythromelalgia.

[0158] Another object of the present invention is a composition according to the invention as described previously for its topical use in the treatment of erythromelalgia.

[0159] The present invention also relates to the use of a composition according to the invention as described above for the preparation of a medicinal product for the treatment or prevention of neuropathic pain possibly induced by chemotherapy.

[0160] More specifically, the invention relates to the use of a composition according to the invention as described above for the preparation of a medicinal product for the treatment of cancer (including chemotherapy courses), which is topically administered between chemotherapy courses to treat or prevent neuropathic pain that may be induced by chemotherapy.

[0161] The present invention also relates to the use of a composition according to the present invention as described above for treating or preventing neuropathic pain that may be induced by chemotherapy.

[0162] More specifically, the invention relates to a composition according to the invention as described above, its use in the treatment of cancer including chemotherapy courses, which composition is topically administered between chemotherapy courses to treat or prevent neuropathic pain that may be induced by chemotherapy.

[0163] The following examples illustrate the composition according to the invention and the advantages of the composition. However, they do not represent a limitation of the invention in any way, but simply illustrate the invention. Example:

[0164] Composition A according to the following invention was prepared from the ingredients shown in the following table, the amounts of which are expressed in weight %.

[0165] Composition A (invention) quantity Amitriptyline 8 Hydroxyethyl Cellulose 1 Propylene glycol 5 Methylparaben 0.1 pH Reagents QSpH 7 water QS100

[0166] In particular, it has been observed that an increase in the pH of amitriptyline-based compositions above 7 enables to maintain good effectiveness in pain treatment in dermal applications and possibly improve effectiveness while reducing the concentration of amitriptyline and thus the risk of adverse effects.

[0167] It was also observed that the composition according to the invention provides good permeation of amitriptyline through the skin even for low levels of amitriptyline.

[0168] The present invention also includes the following embodiments:

[0169] 1. A pharmaceutical composition in the form of an oil-in-water emulsion for topical application, comprising:

[0170] (i) an oil phase containing at least amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 30% by weight relative to the total weight of the composition; and

[0171] (ii) an aqueous phase having a pH greater than or equal to 7.

[0172] 2. The composition according to the preceding embodiment, characterized in that the total content of amitriptyline ranges from 1 wt % to 10 wt %, preferably from 1 wt % to 9 wt %, more preferably from 1 wt % to 8 wt %, even more preferably from 1 wt % to 7 wt %, relative to the total weight of the composition.

[0173] 3. A composition according to any one of the preceding embodiments, characterised in that the volume average size of the oil droplets ranges from 1 nm to 50 μm; preferably ranges from 10 nm to 20 μm; and more preferably ranges from 100 nm to 10 μm.

[0174] 4. A composition according to any one of the preceding embodiments, characterised in that the pH of the aqueous phase is higher than or equal to 8; preferably ranging from 8 to 13; more preferably from 8.5 to 13; even more preferably from 9 to 12.5; and even more preferably from 9 to 12.

[0175] 5. The composition according to any one of the preceding embodiments, characterized in that it further comprises at least one surfactant; preferably selected from nonionic surfactants.

[0176] 6. Composition according to the preceding embodiment, characterised in that it further comprises at least one nonionic surfactant, optionally polyoxyalkylenated, chosen from sorbitan esters, glycerides and mixtures thereof.

[0177] 7. The composition according to any one of the preceding embodiments, characterized in that it further comprises at least one C2-C8 polyol.

[0178] 8. The composition according to any one of the preceding embodiments, characterized in that it further comprises at least one thickener; preferably selected from cellulosic polymers.

[0179] 9. A composition according to any one of the preceding embodiments, characterized in that the moisture content is greater than or equal to 75% by weight, preferably comprised between 75% by weight and 95% by weight; and more preferably comprised between 75% by weight and 90% by weight, relative to the total weight of the composition.

[0180] 10. Composition according to any one of the preceding embodiments, characterized in that amitriptyline in its basic form constitutes the oily phase.

[0181] 11. Composition according to any one of embodiments 1 to 9, characterized in that it comprises at least one liquid fatty substance; preferably chosen from hydrocarbons, fatty esters containing from 8 to 40 carbon atoms, silicones and mixtures thereof.

[0182] 12. Use of a pharmaceutical composition as defined in any one of embodiments 1 to 11 for the preparation of a medicinal product.

[0183] 13. The pharmaceutical composition according to the aforementioned embodiment is used to prepare a pharmaceutical product for local treatment of neuropathic pain; preferably for local treatment of peripheral neuropathic pain caused by chemotherapy, post-herpetic neuropathic pain, diabetic neuropathic pain; more preferably for local treatment of peripheral neuropathic pain caused by chemotherapy.

[0184] 14. Use of the pharmaceutical composition according to embodiment 12 for the preparation of a medicinal product for topical treatment of erythromelalgia.

Claims

1. A pharmaceutical composition in the form of an oil-in-water emulsion for topical application, comprising: (i) an oil phase containing at least amitriptyline in basic form, the total content of amitriptyline ranging from 1% to 30% by weight relative to the total weight of the composition; and (ii) an aqueous phase having a pH greater than or equal to 7.

2. The composition according to the preceding claim, characterized in that Relative to the total weight of the composition, the total content of amitriptyline ranges from 1 to 10 wt%, preferably from 1 to 9 wt%, more preferably from 1 to 8 wt%, even more preferably from 1 to 7 wt%.

3. A composition according to any one of the preceding claims, characterised in that The volume average size of the oil droplets ranges from 1 nm to 50 μm; preferably ranges from 10 nm to 20 μm; and more preferably from 100 nm to 10 μm.

4. A composition according to any one of the preceding claims, characterised in that The pH of the aqueous phase is higher than or equal to 8; preferably ranges from 8 to 13; more preferably from 8.5 to 13; even more preferably from 9 to 12.5; and even more preferably from 9 to 12.

5. A composition according to any one of the preceding claims, characterised in that It further comprises at least one surfactant; preferably selected from nonionic surfactants.

6. Composition according to the preceding claim, characterized in that It further comprises at least one nonionic surfactant, optionally polyoxyalkylenated, chosen from sorbitan esters, glycerol esters and mixtures thereof.

7. A composition according to any one of the preceding claims, characterised in that It further comprises at least one C2-C8 polyol.

8. Use of a pharmaceutical composition as defined in any one of claims 1 to 7 for the preparation of a medicinal product.

9. Use of the pharmaceutical composition according to the preceding claims for the preparation of a medicinal product for the local treatment of neuropathic pain; preferably for the local treatment of chemotherapy-induced peripheral neuropathic pain, post-herpetic neuropathic pain, diabetic neuropathic pain; more preferably for the local treatment of chemotherapy-induced peripheral neuropathic pain.

10. Use of the pharmaceutical composition according to claim 8 for the preparation of a medicinal product for topical treatment of erythromelalgia.